Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BIBW 2992 Extends PFS in NSCLC Patients: BI
October 25, 2010
- Risk Classification for 7 APIs Reviewed
October 25, 2010
- Zibotentan Fails to Extend OS in CRPC Patients
October 18, 2010
- SANTEC Transfers CRO Business to Clio Science
October 18, 2010
- Ticagrelor Receives Positive Opinion from CHMP
October 18, 2010
- Points Should Not Be Given for Out-of-Pocket Payments for Dispensing Services: JPA
October 18, 2010
- NHI Price Listing of Generic Aricept Remains Uncertain
October 18, 2010
- Korosho Revises Package Insert for Victoza Following Report of 2 Deaths
October 18, 2010
- Linagliptin Improves HbA1c with and without SU
October 18, 2010
- ASKLEP Sets Up Subsidiary in China
October 18, 2010
- PMDA to Accept Regulatory Officials from KFDA for Training
October 18, 2010
- Early Addition of Saxagliptin Effective in Achieving Target HbA1c Levels
October 18, 2010
- Apo Plus Station Carries Out MBO
October 18, 2010
- NEW PRODUCTS
October 18, 2010
- Gov't to Create Fund to Subsidize Vaccination against HPV
October 18, 2010
- Sandoz Launches First Ramosetron Generic in Japan
October 18, 2010
- Takeda Ties Up with Envoy to Develop Schizophrenia Drugs
October 18, 2010
- Market for OTC Kampo Medicines to Grow 0.8% to ¥239.4 Bil. in 2010
October 18, 2010
- Ranbaxy Granted 180-Day Exclusivity for Generic Aricept in the US
October 18, 2010
- Asubio Pharma Starts Operation in Kobe
October 18, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…